Bisrat G Debeb, DVM, PhD
Department of Breast Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Experimental Radiation Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2008 | Texas A&M University, College Station, Texas, US, Biomedical Sciences, Ph.D |
| 2005 | Tuskegee University, Tuskegee, Alabama, US, Epidemiology, M.Sc |
| 1999 | Addis Ababa University, Addis Ababa, ET, Veterinary Medicine, DVM |
Postgraduate Training
| 2008-2011 | Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Experience & Service
Administrative Appointments/Responsibilities
Interim Head, Department of Microbiology, Veterinary Public Health and Infectious Disease, Addis Ababa University, Addis Ababa, 2002 - 2002
Other Appointments/Responsibilities
Member, PCCSM Summer Student Selection Committee, MD Anderson, Houston, TX, 2023 - Present
Poster Judge, Trainee Research Day, MD Anderson, Houston, TX, 2022 - Present
Member, IBC Seminar Series Committee, MD Anderson, Houston, TX, 2019 - 2020
Vice-President, Graduate Students Association, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, 2006 - 2007
Associate Director, International Teaching Assistants (ITA) Forum, Center for Teaching Excellence, Texas A&M University, College Station, TX, 2006 - 2007
Mentor, International Teaching Assistants Training and Evaluation Program, Texas A&M University, College Station, TX, 2006 - 2007
Institutional Committee Activities
Member, Inflammatory Breast Cancer (IBC) Strategic Committee, 2022 - Present
Member, Faculty Member of Institutional Biosafety Committee (IBC), 2019 - Present
Member, Faculty Academic Review Committee (Faculty ARC), 2019 - Present
Member, Faculty Representative of Postdoctoral Advisory Committee, 2014 - 2016
Member, Faculty Member, Global Health Committee, 2011 - Present
Honors & Awards
| 2023 | EIAP (Early Investigator Advancement Program) Scholar, NIH/NCI |
| 2023 | IBC Team Science Award, Morgan Welch Inflammatory Breast Cancer Program and Clinic, The University of Texas MD Anderson Cancer Center |
| 2022 | IBC Team Science Award, Morgan Welch Inflammatory Breast Cancer Program and Clinic, The University of Texas MD Anderson Cancer Center |
| 2021 | 'Scientists to Watch’ 2021, The Scientist Magazine |
| 2021 | IBC Team Science Award, Morgan Welch Inflammatory Breast Cancer Program and Clinic, The University of Texas MD Anderson Cancer Center |
| 2020 | American Cancer Society Research Scholar, American Cancer Society |
| 2017 | 5th Annual Zeta Tau Alpha Houston Alumnae Association Fellowship in IBC Research |
| 2017 | Jon Shevell Young Scientist Travel Scholarship, Susan G. Komen Foundation |
| 2017 | IBC Fellowship, 5th Annual Zeta Tau Alpha Houston Aluminae Association in Inflammatory Breast Cancer Research, Zeta Tau Alpha Houston Aluminae Association in Inflammatory Breast Cancer Research |
| 2016 | Pillar of Support Award, Forum of First Ladies Against Breast and Cervical Cancer, Ethiopia |
| 2016 | Partnerships to Advance Cancer Health Equity Travel Award |
| 2015 | 1st Place Poster Prize Award, NCI CRCHD |
| 2015 | AACR Minority Scholar in Cancer Research Award, 2015 AACR Annual Meeting |
| 2015 | AACR Minority Scholar in Cancer Research Award, AACR Special Conference on Tumor Metastasis |
| 2014 | Young Investigator Award, 4th Annual Brain Metastasis Conference, Marseille, France |
| 2014 | Susan G. Komen Postdoctoral Fellowship Award, Susan G. Komen Foundation |
| 2014 | Junior Investigator Grant Award, IBC Network Foundation |
| 2013 | Carl Storm Underrepresented Minority Fellowship |
| 2013 | Susan G. Komen Postdoctoral Fellowship Award, Susan G. Komen Foundation |
| 2012 | Susan G. Komen Postdoctoral Fellowship Award, Susan G. Komen Foundation |
| 2011 | AACR Minority Scholar in Cancer Research Award, AACR |
| 2011 | Susan G. Komen Postdoctoral Fellowship Award, Susan G. Komen Foundation |
| 2010 | Susan G. Komen Postdoctoral Fellowship Award, Susan G. Komen Foundation |
| 2007 | 1st Place Oral Presentation Award, GSA Research Symposium, Texas A&M University, College of Veterinary Medicine and Biomedical Sciences |
| 2007 | Travel Award, 47th Annual American Society of Cell Biology Meeting, Texas A&M College of Veterinary Medicine, Graduate Student Association |
| 2003 | Graduate Fellowship Award, USAID/Tuskegee University |
| 1999 | Dean's List and Academic Excellence Award, Addis Ababa University |
| 1999 | Award of Recognition for Academic Excellence, University of Tennessee, College of Veterinary Medicine |
| 1999 | Gold Medalist, DVM Class of 1999, Addis Ababa University, Faculty of Veterinary Medicine |
| 1998 | Dean's List and Academic Excellence Award, Addis Ababa University |
| 1997 | Dean's List and Academic Excellence Award, Addis Ababa University |
| 1996 | Dean's List and Academic Excellence Award, Addis Ababa University |
| 1995 | Dean's List and Academic Excellence Award, Addis Ababa University |
| 1994 | Dean's List and Academic Excellence Award, Addis Ababa University |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Yin, L, Hu, X, Pei, G, Tang, M, Zhou, Y, Zhang, H, Huang, M, Li, S, Zhang, J, Citu, C, Zhao, Z, Debeb, BG, Feng, X, Chen, J. Genome-wide CRISPR screen reveals the synthetic lethality between BCL2L1 inhibition and radiotherapy. Life science alliance 7(4), 2024. PMID: 38316463.
- Balema W, Morton J, Larson RA, Li L, Velasquez FC, Fowlkes NW, Krishnamurthy S, Debeb BG, Sevick-Muraca E, Woodward WA. High-fat diet, but not duration of lactation, increases mammary gland lymphatic vessel function and subsequent growth of inflammatory breast cancer cells. J Mammary Gland Biol Neoplasia 28(1):21, 2023. e-Pub 2023. PMID: 37801190.
- Gadde M, Mehrabi-Dehdezi M, Debeb BG, Woodward WA, Rylander MN. Influence of Macrophages on Vascular Invasion of Inflammatory Breast Cancer Emboli Measured Using an In Vitro Microfluidic Multi-Cellular Platform. Cancers (Basel) 15(19), 2023. e-Pub 2023. PMID: 37835577.
- Villodre ES, Hu X, Huo L, Debeb BG. Response to de Nonneville, Finetti, Mamessier and Bertucci. J Natl Cancer Inst 114(7):1048-1049, 2022. e-Pub 2022. PMID: 35148408.
- Villodre ES, Hu X, Eckhardt BL, Larson R, Huo L, Yoon EC, Gong Y, Song J, Liu S, Ueno NT, Krishnamurthy S, Pusch S, Tripathy D, Woodward WA, Debeb BG. NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. J Natl Cancer Inst 114(4):579-591, 2022. e-Pub 2022. PMID: 34893874.
- Villodre ES, Hu X, Larson R, Finetti P, Gomez K, Balema W, Stecklein SR, Santiago-Sanchez G, Krishnamurthy S, Song J, Su X, Ueno NT, Tripathy D, Van Laere S, Bertucci F, Vivas-Mejía P, Woodward WA, Debeb BG. Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. Mol Oncol 15(10):2752-2765, 2021. e-Pub 2021. PMID: 34342930.
- Balema W, Liu D, Shen Y, El-Zein R, Debeb BG, Kai M, Overmoyer B, Miller KD, Le-Petross HT, Ueno NT, Woodward WA. Inflammatory breast cancer appearance at presentation is associated with overall survival. Cancer Med 10(18):6261-6272, 2021. e-Pub 2021. PMID: 34327874.
- Santiago-Sánchez GS, Noriega-Rivera R, Hernández-O'Farrill E, Valiyeva F, Quiñones-Diaz B, Villodre ES, Debeb BG, Rosado-Albacarys A, Vivas-Mejía PE. Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors. Int J Mol Sci 22(16), 2021. e-Pub 2021. PMID: 34445288.
- Fukumura K, Malgulwar PB, Fischer GM, Hu X, Mao X, Song X, Hernandez SD, Zhang XH, Zhang J, Parra ER, Yu D, Debeb BG, Davies MA, Huse JT. Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathol 141(2):303-321, 2021. e-Pub 2021. PMID: 33394124.
- Hu X, Villodre ES, Woodward WA, Debeb BG. Modeling brain metastasis via tail-vein injection of inflammatory breast cancer cells. J Vis Exp 2021(168):1-12, 2021. e-Pub 2021. PMID: 33616115.
- Hu X, Villodre ES, Larson R, Rahal OM, Wang X, Gong Y, Song J, Krishnamurthy S, Ueno NT, Tripathy D, Woodward WA, Debeb BG. Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer. Commun Biol 4(72):72, 2021. e-Pub 2021. PMID: 33452400.
- Smith DL, Debeb BG, Diagaradjane P, Larson R, Kumar S, Ning J, Lacerda L, Li L, Woodward WA. Prophylactic cranial irradiation reduces the incidence of brain metastasis in a mouse model of metastatic, HER2-positive breast cancer. Genes Cancer 12:28-38, 2021. e-Pub 2021. PMID: 33884104.
- Villodre ES, Gong Y, Hu X, Huo L, Yoon EC, Ueno NT, Woodward WA, Tripathy D, Song J, Debeb BG. NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer. Cancers (Basel) 12(12), 2020. e-Pub 2020. PMID: 33321961.
- Gagliardi M, Pitner MK, Park J, Xie X, Saso H, Larson RA, Sammons RM, Chen H, Wei C, Masuda H, Chauhan G, Kondo K, Tripathy D, Ueno NT, Dalby KN, Debeb BG, Bartholomeusz C. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Sci Rep 10(1):8537, 2020. e-Pub 2020. PMID: 32444778.
- Bertucci F, Rypens C, Finetti P, Guille A, Adélaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, Cristofanilli M, Chaffanet M, Birnbaum D, Van Laere S. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. Mol Oncol 14(3):504-519, 2020. e-Pub 2020. PMID: 31854063.
- Reddy JP, Atkinson RL, Larson R, Burks JK, Smith D, Debeb BG, Ruffell B, Creighton CJ, Bambhroliya A, Reuben JM, Van Laere SJ, Krishnamurthy S, Symmans WF, Brewster AM, Woodward WA. Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer. Breast Cancer Res Treat 171(2):283-293, 2018. e-Pub 2018. PMID: 29858753.
- Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, Li CW, Lai YJ, Wei W, Wang J, Manyam GC, Diao L, Zhang X, Lin F, Symmans WF, Sun L, Liu CG, Liu X, Debeb BG, Ueno NT, Harano K, Alvarez RH, Wu Y, Cristofanilli M, Huo L. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol 77:121-129, 2018. e-Pub 2018. PMID: 29689244.
- Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer 124(11):2299-2305, 2018. e-Pub 2018. PMID: 29579338.
- Bambhroliya A, Van Wyhe RD, Kumar S, Debeb BG, Reddy JP, Van Laere S, El-Zein R, Rao A, Woodward WA. Gene set analysis of post-lactational mammary gland involution gene signatures in inflammatory and triple-negative breast cancer. PLoS One 13(4):e0192689, 2018. e-Pub 2018. PMID: 29617367.
- Caceres S, Peña L, Lacerda L, Illera MJ, de Andres PJ, Larson RA, Gao H, Debeb BG, Woodward WA, Reuben JM, Illera JC. Canine cell line, IPC-366, as a good model for the study of inflammatory breast cancer. Vet Comp Oncol 15(3):980-995, 2017. e-Pub 2016. PMID: 27146723.
- Woodward WA, Cristofanilli M, Merajver SD, Laere SV, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, and Ueno NT. Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. J Cancer 8(17):3607–3614, 2017. PMID: None.
- Stecklein SR, Reddy JP, Wolfe AR, Lopez MS, Fouad TM, Debeb BG, Ueno NT, Brewster AM, Woodward WA. Lack of Breastfeeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival. J Cancer 8(10):1726-1732, 2017. e-Pub 2017. PMID: 28819368.
- Jolly MK, Boareto M, Debeb BG, Aceto N, Farach-Carson MC, Woodward WA, Levine H. Inflammatory breast cancer: a model for investigating cluster-based dissemination. NPJ Breast Cancer 3(None):21, 2017. e-Pub 2017. PMID: 28649661.
- Wolfe AR, Trenton NJ, Debeb BG, Larson R, Ruffell B, Chu K, Hittelman W, Diehl M, Reuben JM, Ueno NT, Woodward WA. Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget 7(50):82482-82492, 2016. PMID: 27756885.
- Smith DL, Debeb BG, Thames HD, Woodward WA. Computational modeling of micrometastatic breast cancer radiation dose-response. Int J Radiat Oncol Biol Phys 96(1):179-87, 2016. e-Pub 2016. PMID: 27511855.
- Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Bambhroliya A, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Wu W, Calin GA, Krishnamurthy S, Zhang XH, Buchholz TA, Ueno NT, Reuben JM, Woodward WA. miR-141-mediated regulation of brain metastasis from breast cancer. J Natl Cancer Inst 108(8), 2016. e-Pub 2016. PMID: 27075851.
- Wolfe AR, Bambhroliya A, Reddy JP, Debeb BG, Huo L, Larson R, Li L, Ueno NT, Woodward WA. MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer. Int J Radiat Oncol Biol Phys 95(2):791-9, 2016. e-Pub 2016. PMID: 27055396.
- Debeb BG, Lacerda L, Larson R, Wolfe AR, Krishnamurthy S, Reuben JM, Ueno NT, Gilcrease M, Woodward WA. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget 7(19):28329-39, 2016. e-Pub 2016. PMID: 27078845.
- Huo L, Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, Liu CG, Liu X, Lin F, Symmans WF, Wei W, Zhang X, Sun L, Alvarez RH, Ueno NT, Fouad TM, Harano K, Debeb BG, Wu Y, Reuben J, Cristofanilli M, Zuo Z. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol 29(4):330-46, 2016. e-Pub 2016. PMID: 26916073.
- Wolfe AR, Debeb BG, Lacerda L, Larson R, Bambhroliya A, Huang X, Bertucci F, Finetti P, Birnbaum D, Van Laere S, Diagaradjan P, Ruffell B, Trenton NJ, Chu K, Hittelman W, Diehl M, Levental I, Ueno NT, Woodward WA. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Res Treat 154(3):495-508, 2015. e-Pub 2015. PMID: 26590814.
- Reddy JP, Dawood S, Mitchell M, Debeb BG, Bloom E, Gonzalez-Angulo AM, Sulman EP, Buchholz TA, Woodward WA. Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy. Radiother Oncol 117(2):308-14, 2015. e-Pub 2015. PMID: 26482599.
- Wolfe AR, Atkinson RL, Reddy JP, Debeb BG, Larson R, Li L, Masuda H, Brewer T, Atkinson BJ, Brewster A, Ueno NT, Woodward WA. High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. Int J Radiat Oncol Biol Phys 91(5):1072-80, 2015. PMID: 25832697.
- Lacerda L, Debeb BG, Smith D, Larson R, Solley T, Xu W, Krishnamurthy S, Gong Y, Levy LB, Buchholz T, Ueno NT, Klopp A, Woodward WA. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Res 17:42, 2015. e-Pub 2015. PMID: 25887413.
- Cohen EN, Gao H, Anfossi S, Mego M, Reddy NG, Debeb BG, Giordano A, Tin S, Wu Q, Garza RJ, Cristofanilli M, Mani SA, Croix DA, Ueno NT, Woodward WA, Luthra R, Krishnamurthy S, Reuben JM. Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. PLoS One 10(7):e0132710, 2015. e-Pub 2015. PMID: 26207636.
- Debeb BG, Smith DL, Li L, Larson R, Xu W, Woodward WA. Differential effect of phosphorylation-defective survivin on radiation response in estrogen receptor-positive and -negative breast cancer. PLoS One 10(3):e0120719, 2015. e-Pub 2015. PMID: 25763854.
- Zhang P, Wei Y, Wang L, Debeb BG, Yuan Y, Zhang J, Yuan J, Wang M, Chen D, Sun Y, Woodward WA, Liu Y, Dean DC, Liang H, Hu Y, Ang KK, Hung MC, Chen J, Ma L. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol 16(9):864-75, 2014. e-Pub 2014. PMID: 25086746.
- Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, Brewer T, Debeb BG, Xu W, Hortobágyi GN, Buchholz TA, Ueno NT, Woodward WA. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med 3(7):849-56, 2014. e-Pub 2014. PMID: 24833589.
Grant & Contract Support
| Title: | Targeting Novel Mediators of Breast Cancer Brain Metastasis |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| Title: | Dual HER2/VEGFR2 Kinase Inhibitors Targeting Resistant Breast Cancer and Its Aggressive Brain Metastasis: From Design to Formulation |
| Funding Source: | US-Egypt Collaborative Research Grant |
| Role: | Co-I |
| Title: | Preclinical/Translational research breakthroughs in IBC |
| Funding Source: | MDACC - Morgan Welch IBC Program |
| Role: | PI |
| Title: | Targeting sEcad - PDI axis for the treatment of breast cancer brain metastasis |
| Funding Source: | METAvivor Translational Research Award |
| Role: | PI |
| Title: | Cholesterol mediated radiation resistance in brain metastases |
| Funding Source: | MDACC-ROSI Shark Tank Seed Award |
| Role: | Co-PI |
| Title: | Novel mechanisms of brain metastasis in aggressive breast cancers |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| Title: | Role of sEcad in NK-mediated cytotoxicity |
| Funding Source: | MDACC - Morgan Welch IBC Program |
| Role: | Co-PI |
| Title: | The role of NDRG1 driven stemness in aggressive breast tumors |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| Title: | Screening for breast cancer brain-metastasis small molecule inhibitors |
| Funding Source: | MDACC - Morgan Welch IBC Program |
| Role: | PI |
| Title: | Development and optimization of 12-marker multiplex flow cytometry |
| Funding Source: | MDACC - Morgan Welch IBC Program |
| Role: | PI |
| Title: | Serum Biomarker Profiles in IBC Patients |
| Funding Source: | MDACC - Morgan Welch IBC Program |
| Role: | Co-PI |
| Title: | Targeting Protein Disulfide Isomerase in Breast Cancer Brain Metastasis |
| Funding Source: | MDACC-Bridge Funding |
| Role: | PI |
| Title: | Targeting soluble E-cadherin in inflammatory breast cancer |
| Funding Source: | MWIBC-BootWalk Fund |
| Role: | PI |
| Title: | NDRG1/ PKC promote IBC brain metastases |
| Funding Source: | Morgan Welch IBC |
| Role: | PI |
| Title: | NDRG1/PKC in Brain Metastasis |
| Funding Source: | MWIBC-Team Science Grant |
| Role: | PI |
| Title: | Deciphering the role of NDRG1 in inflammatory breast cancer tumor initiation and progression |
| Funding Source: | MD Anderson-IRG |
| Role: | PI |
| Title: | Therapeutic efficacy of decorin recombinant protein for inflammatory breast cancer |
| Funding Source: | Morgan Welch Inflammatory Breast Cancer Boot Walk Fund |
| Role: | Mentor |
| Title: | Targeting PI3K/mTOR to prevent NDRG1-mediated tumor progression and metastasis in inflammatory breast cancer |
| Funding Source: | Morgan Welch Inflammatory Breast Cancer Boot Walk Fund |
| Role: | Mentor |
| Title: | Molecular and Immunohistochemical features of Breast Cancer in Ethiopia |
| Funding Source: | MDACC-SINF |
| Role: | PI |
| Title: | Identification and targeting functional drivers of brain metastasis from breast cancer |
| Funding Source: | MDACC-Startup |
| Role: | PI |
| Title: | Early stage brain metastasis initiation and colonization from breast cancer |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | PI |
| Title: | Targeting Lipocalin2 to prevent brain metastasis in inflammatory breast cancer |
| Funding Source: | MDACC U54 Pilot Grant |
| Role: | PI |
| Title: | U54 Pilot Project D - Targeting Lipocalin2 to prevent brain metastasis in inflammatory breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | LCN2 in inflammatory breast cancer |
| Funding Source: | MDACC U54 Supplement |
| Role: | PI |
| Title: | Randomized Phase II Double Blind Study of VPA vs Placebo to Shorten Time of Indwelling Pleural Catheter (Clinical Trial NCT01900730) |
| Funding Source: | IBC Network Foundation |
| Role: | Co-I |
| Title: | Seed money to generate additional brain metastasis models and to understand brain metastasis in inflammatory breast cancer |
| Funding Source: | Morgan Welch IBC Research Program and Clinic |
| Role: | PI |
| Title: | (PQD4) Signs of Inflammatory Breast Cancer are Caused by Stromal Field Effects |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Elucidate the role of miR-141 in Brain Metastasis from Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Elucidate in the role of miR-141 in brain metastasis from breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Therapeutic efficacy of oligonucleotides to prevent brain metastasis from breast cancer |
| Funding Source: | IBC Network Foundation |
| Role: | PI |
| Title: | Targeting microRNA to alter radiation resistance of breast cancer stem cells |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | PI |
| Title: | Elucidating mechanisms that drive breast cancer brain metastasis |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Dual HER2/VEGFR2 Kinase Inhibitors Targeting Resistant Breast Cancer and Its Aggressive Brain Metastasis: From Design to Formulation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Local delivery of extracellular vesicles loaded with anti-miRNAs secreted by engineered T cells to target triple-negative breast cancer: a novel strategy |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-PI |
| Title: | Multi-Targeting of Resistant Breast Cancer Brain Metastases (RBCWM) with Innovative Dual Anti-HER2/VEGFR2 then anti-EMT Therapy |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Title: | Sequential Targeting of Breast Cancer Brain Metastases by Innovative Anti-HER2/VEGFR2 and -Secretase Modulator |
| Funding Source: | TAMUHSC |
| Role: | PI |
| Title: | Characterizing sEcad in brain metastatic breast cancer”, Cancer Prevention & Research Institute of Texas (CPRIT) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Title: | The role of cytokine-mediated networks in aggressive breast cancers |
| Funding Source: | Multidisciplinary Research Program |
| Role: | Co-PI |
| Title: | Targeting Protein Disulfide Isomerase in Breast Cancer Brain Metastasis |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| Title: | Dual Anti-HER2/VEGFR Targeted Therapy for Resistant Metastatic Breast Cancer (RMBC) |
| Funding Source: | TAMUHSC |
| Role: | Co-I |
| Title: | Dual HER2/VEGFR2 Kinase Inhibitors Targeting Breast Cancer Brain Metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Identifying targetable tumor-brain microenvironment interactions that promote breast cancer brain metastasis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Title: | Emerging strategies of Targeted Dual Anti-HER2/VEGF for Breast Cancer Brain Metastases |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Multi-Tissue In Vitro Platforms for Modeling the Metastatic Cascade in Aggressive Breast Cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Title: | Biomimetic Microfluidic Platform for Mechanistic Study of Breast Tumor Metastasis to Brain |
| Funding Source: | UT-Austin-MDACC Collaborative Pilot |
| Role: | Co-PI |
| Title: | Identifying therapeutic targets for brain metastasis |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Novel mediators of inflammatory breast cancer aggressiveness |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| Title: | Blood Brain Barrier Modulating miRNA-based Therapeutics for the Treatment of Brain Metastases in Breast Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Title: | Characterizing sEcad in brain metastatic breast cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Title: | Emerin dysfunction drives breast cancer metastasis |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Title: | Biomimetic Blood Brain Barrier Assay for Drug Discovery in Treating Brain Metastasis in Breast Cancer |
| Funding Source: | NCI/IMAT |
| Role: | PI |
| Title: | Novel Mechanisms and Therapeutic Targets of Breast Cancer Brain Metastasis |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | PI |
| Title: | Development of Multi-Epitope Targeting Bi-Specific MAbOligo Therapeutics for Brain Metastatic Breast Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Title: | Elucidating Targetable Tumor cell - Microenvironment Interactions in Brain Metastases |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| Title: | Identifying targetable tumor-microenvironment interactions that promote breast cancer brain metastasis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| Title: | Development of Multi-Epitope Targeting Bi-Specific MAbOligo Therapeutics for Brain Metastatic Breast Cancer |
| Funding Source: | NIH-SBIR |
| Role: | Co-I |
| Title: | Therapeutic exploitation of NDRG1- mediated tumorigenesis in aggressive breast cancers |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| Title: | Mechanisms of tumor initiation and maintenance in inflammatory breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Influence of normal breast biology on health disparity in inflammatory breast cancer (IBC) |
| Funding Source: | Susan G. Komen-Genentech Health Disparities Grant |
| Role: | PI |
| Title: | Molecular determinants of brain metastasis in aggressive breast cancers |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Improving therapeutic efficacy in inflammatory breast cancer |
| Funding Source: | MD Anderson-IRG |
| Role: | PI |
| Title: | Development of a Multifunctional Hybrid Nanoparticle (MHN) to treat inflammatory breast cancer metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | E-cadherin as a viable target in brain metastasis from breast cancer |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | PI |
| Title: | E-cadherin as a viable target in brain metastasis from breast cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| Title: | Defining the role of EMT/MET in brain metastasis |
| Funding Source: | MDACC |
| Role: | Principal Investigator-MDACC |
| Title: | Targeting EZH2 to modulate the response of inflammatory breast cancer stem cells to radiation |
| Funding Source: | ASTRO 2013 Junior Faculty Career Research Training Award |
| Role: | PI |
| Title: | Malignant Reprogramming Triggers a Switch in Glucose Metabolism |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | miR-141 in Brain Metastasis from Breast cancer |
| Funding Source: | Sidney Kimmel Scholar Award |
| Role: | PI |
| Title: | The miR-200 microRNAs as a potential therapeutic target in inflammatory breast cancer |
| Funding Source: | MDACC-Inflammatory Breast Cancer Research Program |
| Role: | PI |
| Title: | Mechanisms of Cholesterol mediated metastasis and Radiation resistance |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| Title: | Mechanisms and Therapeutic Targets of Breast Cancer Brain Metastasis |
| Funding Source: | Andrew Sabin Fellowship Award |
| Role: | PI |
| Title: | NDRG1 as a Master Regulator of Tumor Stemness in Aggressive Breast Cancers |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | NDRG1 as a Master Regulator of Tumor Stemness in Aggressive Breast Cancers |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| Title: | Harnessing oncolytic Viro-immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Enhanced Viro-Immunotherapy for Breast Cancer Brain Metastasis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Title: | Deciphering the Mechanism of Lymphovascular Space Invasion Using a Lympho-vascularized Bioengineering Breast Stromal Platform |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Title: | Multi-Tissue In Vitro Platforms for Modeling the Metastatic Cascade in Aggressive Breast Cancers |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| Title: | Multi-Modal Approaches for Targeting Breast Cancer Brain Metastases and HER2 Mutants |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
Patient Reviews
CV information above last modified August 13, 2024